Clinical Trial Update: A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 study evaluating tradipitant for nausea and vomiting after GLP-1 receptor agonist use in obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Tradipitant (tradipitant)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Obesity | Phase 2 | Status: COMPLETED